首页> 外文期刊>Expert opinion on investigational drugs >Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses.
【24h】

Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses.

机译:抗流感,天花和出血热病毒的抗病毒药的发展。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: the search for effective inhibitors to multiple infectious agents including influenza, smallpox and hemorrhagic fever viruses is an area of active research as many of these agents pose dramatic health and economic challenges to the human population. Many of these infectious agents are not only endemic threats in different parts of the globe, but are also considered to have the potential of being used as bioterrorism agents. AREAS COVERED: this review focuses on inhibitors that are currently in use in the research community against specific emerging infectious agents and those that have bioterrorism potential. The paper provides information about the availability of FDA approved drugs, whenever applicable, and insights into the specific aspect of the agent life cycle that is affected by drug treatment, when known. EXPERT OPINION: the key message that is conveyed in this review is that a combination of pathogen and host-based inhibitors may have to be used for successful control of viral replication to limit the development of drug resistance.
机译:简介:寻找有效的抑制剂来抑制多种传染病,包括流感,天花和出血热病毒,是一项积极的研究领域,因为其中许多对人类构成了巨大的健康和经济挑战。这些感染因子中的许多不仅是全球不同地区的地方性威胁,而且还被认为有可能被用作生物恐怖分子。覆盖的领域:这篇综述着重于研究领域中目前正在使用的抑制剂,以针对特定的新兴传染性病原体以及具有生物恐怖潜力的那些病原体。本文提供了有关FDA批准的药物(如果适用)的可用性的信息,以及对已知受药物治疗影响的药物生命周期特定方面的见解。专家意见:本评论传达的关键信息是,可能必须使用病原体和基于宿主的抑制剂的组合来成功控制病毒复制,以限制耐药性的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号